An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection

Antiviral Research

Volumn 90, Issue 3, 2011, Pages 143-150

  Cai, Yingyun ^a   Berger, Edward A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Ganciclovir; Glycoprotein H; Immunotoxin; Kaposi's sarcoma associated herpesvirus; Lytic infection; Multicentric Castleman's disease

Indexed keywords

ANTIVIRUS AGENT; GLYCOPROTEIN; GLYCOPROTEIN H; IMMUNOTOXIN; UNCLASSIFIED DRUG; YC15 PE38;

ANIMAL CELL; ARTICLE; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN HERPESVIRUS 8; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VIRUS INHIBITION; VIRUS REPLICATION;

ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; EXOTOXINS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOTOXINS; VIRAL ENVELOPE PROTEINS; VIRULENCE FACTORS; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8; PSEUDOMONAS AERUGINOSA;

EID: 79953871010     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.03.175     Document Type: Article

References (49)

1. Alley S.C., Okeley N.M., Senter P.D. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 2010, 14:529-537.
2. Andrei G., De Clercq E., Snoeck R. Novel inhibitors of human CMV. Curr. Opin. Invest. Drugs 2008, 9:132-145.
3. Ashorn P., Moss B., Weinstein J.N., Chaudhary V.K., FitzGerald D.J., Pastan I., Berger E.A. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 1990, 87:8889-8893.
4. Aullo P., Alcami J., Popoff M.R., Klatzmann D.R., Murphy J.R., Boquet P. A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. EMBO J. 1992, 11:575-583.
5. Bera T.K., Kennedy P.E., Berger E.A., Barbas C.F.I., Pastan I. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol. Med. 1998, 4:384-391.
6. Berger E.A., Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PloS Pathog. 2010, 6.
7. Bestawros A., Miche R., Seguin C., Routy J.P. Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. Am. J. Hematol. 2008, 83:508-511.
8. Bower M. How I treat HIV-associated multicentric Castleman's disease. Blood 2010, 116:4415-4421.
9. Bower M., Powles T., Williams S., Davis T.N., Atkins M., Montoto S., Orkin C., Webb A., Fisher M., Nelson M., et al. Rituximab in HIV-associated multicentric Castleman disease. Ann. Intern. Med. 2007, 147:836-839.
10. Burbelo P.D., Issa A.T., Ching K.H., Wyvill K.M., Little R.F., Iadarola M.J., Kovacs J.A., Yarchoan R. Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. J. Infect. Dis. 2010, 201:1919-1922.
11. Casper C. New approaches to the treatment of human herpesvirus 8-associated disease. Rev. Med. Virol. 2008, 18:321-329.
12. Casper C., Krantz E.M., Corey L., Kuntz S.R., Wang J., Selke S., Hamilton S., Huang M.L., Wald A. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J. Infect. Dis. 2008, 198:23-30.
13. Casper C., Nichols W.G., Huang M.L., Corey L., Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004, 103:1632-1634.
14. Castleman B., Towne V.W. Case records of the Massachusetts general hospital: case No. 40231. N. Engl. J. Med. 1954, 250:1001-1005.
15. Cesarman E., Chang Y., Moore P.S., Said J.W., Knowles D.M. Kaposi's sarcoma-associated herpesvirus-like DNA-sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 1995, 332:1186-1191.
16. Cesarman E., Knowles D.M. Kaposi's sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Semin. Diagn. Pathol. 1997, 14:54-66.
17. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., Moore P.S. Identification of herpesvirus-like DNA-sequences in AIDS-associated Kaposis-sarcoma. Science 1994, 266:1865-1869.
18. Chang Y., Moore P.S. Kaposi's sarcoma (KS)-associated herpesvirus and its role in KS. Infect. Agents Dis. - Reviews Issues and Commentary 1996, 5:215-222.
19. Chaudhary V.K., Mizukami T., Fuerst T.R., FitzGerald D.J., Moss B., Pastan I., Berger E.A. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 1988, 335:369-372.
20. Dadachova E., Casadevall A. Radioimmunotherapy of infectious diseases. Semin. Nucl. Med. 2009, 39:146-153.
21. Dittmer D.P., Vahrson W., Staudt M., Hilscher C., Fakhari F.D. Kaposi's sarcoma in the era of HAART - an update on mechanisms, diagnostics and treatment. Aids Rev. 2005, 7:56-61.
22. Douglas C.M., Collier R.J. Exotoxin-A of Pseudomonas-aeruginosa - substitution of glutamic aid-553 with aspartic acid drastically reduces toxicity and enzymatic activity. J. Bacteriol. 1987, 169:4967-4971.
23. Gerard L., Berezne A., Galicier L., Meignin V., Obadia M., De Castro N., Jacomet C., Verdon R., Madelaine-Chambrin I., Boulanger E., et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus-associated multicentric Castleman's disease: ANRS 117 CastlemaB trial. J. Clin. Oncol. 2007, 25:3350-3356.
24. Goldstein H., Pettoello-Mantovani M., Bera T.K., Pastan I.H., Berger E.A. Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-scid-hu mice. J. Infect. Dis. 2000, 181:921-926.
25. Herrada J., Cabanillas F., Rice L., Manning J., Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann. Intern. Med. 1998, 128:657-662.
26. Kaleeba J.A.R., Berger E.A. Broad target cell selectivity of Kaposi's sarcoma-associated herpesvirus glycoprotein-mediated cell fusion and virion entry. Virology 2006, 354:7-14.
27. Kenyon C., Pillay K., Jacobs P. Castleman's disease and retroviral therapy. Transfus. Apher. Sci. 2007, 37:81-84.
28. Kreitman R.J., Wilson W.H., Bergeron K., Raggio M., Stetler-Stevenson M., FitzGerald D.J., Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 2001, 345:241-247.
29. Law A.B., Ryan G., Lade S., Prince H.M. Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Int. J. Hematol. 2010, 91:347-348.
30. Lu M., Suen J., Frias C., Pfeiffer R., Tsai M.H., Chuang E., Zeichner S.L. Dissection of the Kaposi's sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir. J. Virol. 2004, 78:13637-13652.
31. Marcelin A.G., Motol J., Guihot A., Caumes E., Viard J.P., Dussaix E., Cadranel J., Frances C., Carcelain G., Calvez V., Dupin N. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. J. Infect. Dis. 2007, 196:1163-1166.
32. Matsuyama M., Suzuki T., Tsuboi H., Ito S., Mamura M., Goto D., Matsumoto I., Tsutsumi A., Sumida T. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern. Med. 2007, 46:771-774.
33. Mylona E.E., Baraboutis I.G., Lekakis L.J., Georgiou O., Papastamopoulos V., Skoutelis A. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008, 10:25-35.
34. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr. Opin. HIV AIDS 2009, 4:16-21.
35. Pastan I., Beers R., Bera T.K. Methods in Molecular Biology 2003, 503-518. Humana Press Inc., Totowa, NJ.
36. Pellett P.E., Roizman B. Fields Virology 2007, 2479-2499. Lippincott Williams & Wilkens, Philadelphia. fifth ed.
37. Pincus S.H., Wehrly K., Chesebro B. Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J. Immunol. 1989, 142:3070-3075.
38. Powles T., Stebbing J., Bazeos A., Hatzimichael E., Mandalia S., Nelson M., Gazzard B., Bower M. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann. Oncol. 2009, 20:775-779.
39. Powles T., Stebbing J., Montoto S., Nelson M., Gazzard B., Orkin C., Webb A., Bower M. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood 2007, 110:4132-4133.
40. Schmidt S.M., Raible A., Kortuem F., Mayer F., Riessen R., Adam P., Gregor M., Bissinger A.L. Successful treatment of multicentric Castleman's disease with combined immunochemotherapy in an AIDS patient with multiorgan failure. Leukemia 2008, 22:1782-1785.
41. Schulz T.F. The pleiotropic effects of Kaposi's sarcoma herpesvirus. J. Pathol. 2006, 208:187-198.
42. Sharkey R.M., Goldenberg D.M. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv. Drug Deliv. Rev. 2008, 60:1407-1420.
43. Smee D.F., Sidwell R.W., Barnett B.B. Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections. Antivir. Res. 1996, 32:165-171.
44. Soulier J., Grollet L., Oksenhendler E., Cacoub P., Cazalshatem D., Babinet P., Dagay M.F., Clauvel J.P., Raphael M., Degos L., et al. Kaposi's sarcoma-associated herpesvirus-like DNA-sequence in multicentri Castleman's disease. Blood 1995, 86:1276-1280.
45. Stebbing J., Pantanowitz L., Dayyani F., Sullivan R.J., Bower M., Dezube B.J. HIV-associated multicentric Castleman's disease. Am. J. Hematol. 2008, 83:498-503.
46. Sullivan R.J., Pantanowitz L., Casper C., Stebbing J., Dezube B.J. Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin. Infect. Dis. 2008, 47:1209-1215.
47. Till M.A., Ghetie V., Gregory T., Patzer E.J., Porter J.P., Uhr J.W., Capon D.J., Vitetta E.S. HIV-infected cells are killed by rCD4-ricin A chain. Science 1988, 242:1166-1168.
48. Vieira J., O'Hearn P.M. Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology 2004, 325:225-240.
49. Wolf P., Elsasser-Beile U. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int. J. Med. Microbiol. 2009, 299:161-176.